Microcephaly
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy.
|
27860360 |
2017 |
Microcephaly
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
PYCR2 Mutations cause a lethal syndrome of microcephaly and failure to thrive.
|
27130255 |
2016 |
Microcephaly
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Here, we report mutations in PYCR2, which encodes an enzyme in the proline biosynthesis pathway, as the cause of a unique syndrome characterized by postnatal microcephaly, hypomyelination, and reduced cerebral white-matter volume.
|
25865492 |
2015 |
Failure to Thrive
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
The characteristic clinical presentation of patients with PYCR2 mutations included failure to thrive, microcephaly, craniofacial dysmorphism, progressive psychomotor disability, hyperkinetic movements, and axial hypotonia with variable appendicular spasticity.
|
27130255 |
2016 |
Leukodystrophy
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy.
|
27860360 |
2017 |
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results offered a preliminary illustration on the mechanism of the PYCR2-dependent autophagy and showed that PYCR2 was a potential therapeutic target of melanoma.
|
26634742 |
2016 |
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Notably, pyrroline-5-carboxylate reductase 2 (PYCR2) and uridine phosphorylase 1 (UPase1) were found to be altered in ESCC.
|
30559182 |
2019 |
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two prognostic biomarkers, PYCR2 and ADH1A, related to proteomic subgrouping and involved in HCC metabolic reprogramming, were identified.
|
31585088 |
2019 |
Pediatric failure to thrive
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The characteristic clinical presentation of patients with PYCR2 mutations included failure to thrive, microcephaly, craniofacial dysmorphism, progressive psychomotor disability, hyperkinetic movements, and axial hypotonia with variable appendicular spasticity.
|
27130255 |
2016 |
Failure to thrive in infant
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The characteristic clinical presentation of patients with PYCR2 mutations included failure to thrive, microcephaly, craniofacial dysmorphism, progressive psychomotor disability, hyperkinetic movements, and axial hypotonia with variable appendicular spasticity.
|
27130255 |
2016 |
LEUKODYSTROPHY, HYPOMYELINATING, 10
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy.
|
27860360 |
2017 |
LEUKODYSTROPHY, HYPOMYELINATING, 10
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Mutations in PYCR2, Encoding Pyrroline-5-Carboxylate Reductase 2, Cause Microcephaly and Hypomyelination.
|
25865492 |
2015 |
Abnormality of brain morphology
|
0.100 |
CausalMutation
|
phenotype |
CLINVAR |
Homozygous variants in pyrroline-5-carboxylate reductase 2 (PYCR2) in patients with progressive microcephaly and hypomyelinating leukodystrophy.
|
27860360 |
2017 |
LEUKODYSTROPHY, HYPOMYELINATING, 10
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Microcephaly
|
0.130 |
Biomarker
|
disease |
HPO |
|
|
|
Failure to Thrive
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
Leukodystrophy
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
Arachnodactyly
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dwarfism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Muscle Spasticity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Babinski Reflex
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Severe intellectual disability
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Vesico-Ureteral Reflux
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hyperreflexia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Agenesis of corpus callosum
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|